Significant reductions in cancer pain, including aromatase inhibitor-induced arthralgia (AIA) [22,23] and lymphedema pain [24], post-mastectomy pain [25] and neuropathy pain [19,26] were reported in the included meta-analyses. The gene discussed is CYP19A1; the disease is neuropathy.